Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Dynavax Technologies (DVAX)

Dynavax Technologies (DVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?

Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.

DVAX : 9.34 (-1.58%)
ADVM : 2.27 (-4.62%)
CRVS : 2.09 (-3.24%)
BNGO : 5.93 (-2.63%)
Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DVAX : 9.34 (-1.58%)
Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021

/PRNewswire/ -- (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on , after the U.S. financial markets...

DVAX : 9.34 (-1.58%)
Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate

and , /PRNewswire/ --  (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines and  (BE), a -based vaccine and pharmaceutical company, today announced...

DVAX : 9.34 (-1.58%)
United States $30 Billion Vaccines Market to 2027 Featuring Pfizer, Merck, Grifols, Sanofi Pasteur, Seqirus, AstraZeneca, GlaxoSmithKline, Dynavax Technologies

/PRNewswire/ -- The report has been added to offering.

DVAX : 9.34 (-1.58%)
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 51,000 shares of Dynavax common stock as inducements...

DVAX : 9.34 (-1.58%)
Eyes Shift to the Healthcare Industry After the Pandemic Prompts a Reconsideration

/PRNewswire/ -- While the economy is slowly coming back to normal, concerns over the hyper-transmissible delta variant are rising. According to the CDC, the number of new cases in rose 10% this week....

PFE : 42.81 (+0.05%)
TOMDF : 0.0290 (+7.41%)
DVAX : 9.34 (-1.58%)
SRNE : 8.21 (-2.15%)
AGEN : 5.18 (-0.19%)
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

DVAX : 9.34 (-1.58%)
Slow Trading Can't Stop S&P, NASDAQ From Setting New Records

Slow Trading Can't Stop S&P, NASDAQ From Setting New Records

EVC : 6.15 (-1.60%)
MU : 77.58 (+0.65%)
WGO : 71.87 (+0.59%)
NTAP : 79.59 (+0.73%)
KBH : 42.44 (-0.24%)
FB : 356.30 (-0.56%)
GBTC : 34.7350 (+1.71%)
TWST : 123.05 (+3.33%)
DVAX : 9.34 (-1.58%)
VIVO : 20.50 (-0.87%)
EDIT : 41.86 (-0.10%)
Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ --  (Nasdaq: DVAX) today announced that, in connection with the appointment of John Slebir as Senior Vice President, General Counsel on , the Company granted him a non-statutory stock option...

DVAX : 9.34 (-1.58%)
Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

/PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that , Chief Executive Officer, will present virtually at the Goldman...

DVAX : 9.34 (-1.58%)
Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030

Reportlinker.com announces the release of the report "Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090627/?utm_source=GNW

DVAX : 9.34 (-1.58%)
IONS : 37.14 (+1.25%)
JAZZ : 169.52 (-0.63%)
MRK : 76.87 (-0.08%)
MGEN : 23.01 (-0.09%)
SRPT : 67.78 (-1.70%)
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany

EMERYVILLE, Calif., /PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement...

DVAX : 9.34 (-1.58%)
Bavarian Nordic Announces Marketing and Distribution Agreement with Dynavax to Launch HEPLISAV B(R) Hepatitis B Vaccine in Germany

COPENHAGEN, Denmark, May 27 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has entered a partnership with Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing...

BVNKF : 46.0000 (-1.94%)
DVAX : 9.34 (-1.58%)
Dynavax to Present at the William Blair 41st Annual Growth Stock Conference

, /PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that , Chief Executive Officer, will participate in a virtual...

DVAX : 9.34 (-1.58%)
Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering

EMERYVILLE, Calif., /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior...

DVAX : 9.34 (-1.58%)
Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

EMERYVILLE, Calif., /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate...

DVAX : 9.34 (-1.58%)
Dynavax Technologies (DVAX) Beats Q1 Earnings and Revenue Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 37.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

DVAX : 9.34 (-1.58%)
Dynavax Technologies: Q1 Earnings Snapshot

EMERYVILLE, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Thursday reported first-quarter net income of $891,000, after reporting a loss in the same period a year earlier.

DVAX : 9.34 (-1.58%)
Dynavax Announces First Quarter 2021 Financial Results

, /PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the first quarter of 2021.

DVAX : 9.34 (-1.58%)

Barchart Exclusives

When Weather and Weather Derivatives Diverge
A look at the softs complex Friday morning shows us markets aren't looking at weather in Brazil to close out the month. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar